PCYC â Ibrutinib NDA Filed â Well Ahead of Expectations, in MCL and (surprise!) in CLL, Too â Expect Rapid FDA Turnaround And Street Numbers to Come Way Forward â Pharmacyclicsâ filing on July 10 is well ahead of the September 30 company forecast, which is also three months ahead of initial forecast (end 2013)[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.